Drugs / Senl_B19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06581081 | Oct 2024 → Aug 2027 expected | B-cell acute lymphoblastic leukemia, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-08 | Hebei Senlang Biotechnology Inc., Ltd. | Regulatory 引领科创发展 森朗生物荣获石家庄高新区“潜在独角兽”企业称号 senlangbio.com ↗
近日，国家药品监督管理局药品审评中心正式批准河北森朗生物科技有限公司“ Senl_B19 自体 T 细胞注射液 ” 开展治疗复发难治 B 细胞急性淋巴细胞白血病的临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-08 | Hebei Senlang Biotechnology Inc., Ltd. | 引领科创发展 森朗生物荣获石家庄高新区“潜在独角兽”企业称号 senlangbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Senl_B19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06581081 ↗ |
| Known as | S1904 | “Senl_B19 autologous CAR-T (S1904) treatment” NCT06581081 ↗ |
| Modality | Cell therapy | “Targeted CD19 CAR-T cell immunotherapy” NCT06581081 ↗ |
| Target | CD19 | “Targeted CD19 CAR-T cell immunotherapy” NCT06581081 ↗ |